Aurogra is a pharmaceutical product containing Sildenafil Citrate, a well-established phosphodiesterase type 5 (PDE5) inhibitor, designed to address erectile dysfunction (ED) in adult males. It functions by enhancing blood flow to the penile tissue upon sexual stimulation, facilitating the achievement and maintenance of an erection sufficient for satisfactory sexual activity. Manufactured under stringent quality control standards, Aurogra offers a reliable and cost-effective therapeutic option. This medication requires a prescription and should be used under appropriate medical supervision to ensure both safety and efficacy.

Features

• Active ingredient: Sildenafil Citrate 100mg
• Formulation: Film-coated tablet for oral administration
• Rapid onset of action, typically within 30–60 minutes
• Duration of effect: Up to 4–6 hours
• Manufactured in compliance with GMP (Good Manufacturing Practices)
• Available in blister packs for stability and convenience

Benefits

• Effectively improves erectile function, enabling satisfactory sexual intercourse
• Enhances confidence and reduces anxiety related to sexual performance
• Supports spontaneous sexual activity due to its rapid onset and predictable duration
• Provides a clinically proven, well-tolerated treatment option for ED
• Cost-effective alternative to brand-name Sildenafil products
• Improves overall quality of life and intimate relationship satisfaction

Common use

Aurogra is primarily indicated for the treatment of erectile dysfunction in adult men. It is used to facilitate the achievement and maintenance of an erection when accompanied by sexual stimulation. It is not intended for use by women, children, or adolescents. Aurogra may also be prescribed off-label for pulmonary arterial hypertension under specific medical guidance, though its primary and most common application remains within sexual medicine.

Dosage and direction

The recommended starting dose of Aurogra is 50mg, taken approximately 30–60 minutes before anticipated sexual activity. Based on efficacy and tolerability, the dose may be adjusted to 100mg or reduced to 25mg. It should not be taken more than once per day. Aurogra may be taken with or without food, though high-fat meals may delay its onset of action. Sexual stimulation is required for the medication to be effective.

Precautions

• Aurogra should not be used concurrently with other PDE5 inhibitors or treatments for erectile dysfunction.
• Use with caution in patients with anatomical deformation of the penis, bleeding disorders, or active peptic ulceration.
• Priapism (prolonged and painful erection lasting more than 4 hours) requires immediate medical attention to avoid permanent damage.
• Cardiovascular status should be evaluated before initiating treatment for erectile dysfunction.
• Not recommended for use in patients with severe hepatic or renal impairment without dose adjustment and medical supervision.

Contraindications

• Hypersensitivity to Sildenafil Citrate or any excipients in Aurogra.
• Concurrent use of organic nitrates or nitric oxide donors in any form.
• Patients with a history of non-arteritic anterior ischemic optic neuropathy (NAION).
• Severe cardiovascular disorders, including unstable angina, recent stroke, or myocardial infarction.
• Hereditary degenerative retinal disorders.

Possible side effect

Common side effects may include headache, flushing, dyspepsia, nasal congestion, dizziness, and visual disturbances such as altered color perception. Less frequently reported effects include myalgia, back pain, and rash. Although rare, serious adverse events such as sudden hearing loss, prolonged erection, or cardiovascular events have been reported. Most side effects are mild to moderate and transient in nature.

Drug interaction

Aurogra may interact with:

• Nitrates and nitric oxide donors, leading to potentially dangerous hypotension.
• Alpha-blockers and antihypertensive agents, increasing the risk of orthostatic hypotension.
• CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, erythromycin), which may increase Sildenafil plasma concentrations.
• Grapefruit juice, which can inhibit CYP3A4 metabolism and elevate drug levels.
• Other PDE5 inhibitors, resulting in additive effects and increased risk of adverse reactions.

Missed dose

Aurogra is intended for use as needed, not on a fixed schedule. Therefore, the concept of a “missed dose” does not apply. It should only be taken prior to anticipated sexual activity and not more than once in a 24-hour period.

Overdose

In cases of overdose, standard supportive measures should be employed. Expected effects may mirror those of common side effects but with increased severity, including severe hypotension, syncope, and prolonged erection. Medical attention should be sought immediately. Hemodialysis is not expected to significantly accelerate elimination due to high protein binding.

Storage

Store Aurogra tablets at room temperature (15–30°C), in a dry place, protected from light and moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.

Disclaimer

This information is intended for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any new medication or changing your treatment plan. Do not disregard or delay seeking medical advice based on content provided here.

Reviews

Clinical studies and user reports indicate that Aurogra is generally well-tolerated and effective in improving erectile function. Many users report satisfactory results with minimal side effects when used as directed under medical supervision. Individual experiences may vary based on underlying health conditions, adherence to dosing instructions, and lifestyle factors.